Ajax Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AJ1-11095, the company’s next-generation JAK inhibitor being developed for patients with myelofibrosis. The rare, debilitating blood cancer affects an estimated 20,000 individuals in the United States and is characterized by bone marrow scarring, anemia, enlarged spleen, and a significant decline in quality of life.
AJ1-11095 represents a notable scientific advancement as the first JAK2 inhibitor in clinical development that selectively binds the Type II conformation of the JAK2 kinase. This contrasts with all currently approved JAK2 inhibitors, which target the Type I conformation. By binding differently, AJ1-11095 may offer an alternative therapeutic approach for patients who no longer respond to existing therapies—a significant challenge in the treatment landscape.
The investigational therapy is currently being evaluated in an ongoing Phase 1 clinical trial involving patients with myelofibrosis who have previously been treated with Type I JAK2 inhibitors and have either not responded or lost their response over time. The trial, listed under clinical identifier NCT06343805, aims to assess safety, tolerability, and early signs of clinical activity in this underserved patient group.
David Steensma, MD, FACP, Chief Medical Officer of Ajax Therapeutics, described the designation as a meaningful milestone for the program. “Orphan Drug Designation is an important milestone in our clinical development of AJ1-11095 for the treatment of myelofibrosis,” he said. “This designation reinforces the compelling need for effective new treatment options for patients suffering from myelofibrosis and supports our continued efforts to advance AJ1-11095 to address the unmet need for patients who would benefit from improved treatment efficacy, or who have not responded to existing therapies.”
The FDA’s Orphan Drug Designation is intended to encourage the development of therapies for rare diseases through incentives such as tax credits, user-fee waivers, and potential market exclusivity upon approval. With limited treatment options available—and many patients eventually becoming resistant to current JAK inhibitors—the designation underscores the importance of advancing innovative therapies like AJ1-11095.
Ajax’s progress reflects a broader industry effort to address resistance mechanisms in myeloproliferative neoplasms and develop more durable, targeted therapies. As the Phase 1 trial continues, AJ1-11095 will be closely watched as a potential new avenue for patients seeking alternative and more effective treatment approaches.